Operaciones Lexicon - LXRX CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Condiciones de trading
| Diferencial | 0.05 | ||||||||
|
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.025457% | ||||||||
|
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.003235% | ||||||||
| Horario tarifa nocturna | 21:00 (UTC) | ||||||||
| Cantidad comercializada mínima | 1 | ||||||||
| Divisa | USD | ||||||||
| Margen | 20% | ||||||||
| Mercado de valores | United States of America | ||||||||
| Comisión por operación | 0% |
*Information provided by Capital.com
Lexicon Pharmaceuticals Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Estadísticas clave
| Cierre previo* | 3.26 |
| Abrir* | 2.58 |
| Cambio de 1 año* | 47.43% |
| Rango del día* | 2.57 - 2.7 |
| Rango de 52 semanas | 1.31-3.79 |
| Volumen medio (10 días) | 2.95M |
| Volumen medio (3 meses) | 22.59M |
| Capitalización de mercado | 549.73M |
| Ratio P/E | -100.00K |
| Acciones en circulación | 189.56M |
| Ingresos | 126.00K |
| EPS | -0.63 |
| Dividendo (Rendimiento %) | N/A |
| Beta | 1.30 |
| Próxima fecha de resultados | Jul 31, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Cierre | Change | Change (%) | Apertura | High | Low |
|---|---|---|---|---|---|---|
| May 31, 2023 | 3.27 | 0.39 | 13.54% | 2.88 | 3.39 | 2.87 |
| May 30, 2023 | 2.86 | -0.52 | -15.38% | 3.38 | 3.43 | 2.65 |
| May 26, 2023 | 3.14 | 0.12 | 3.97% | 3.02 | 3.20 | 2.90 |
| May 25, 2023 | 2.86 | -0.17 | -5.61% | 3.03 | 3.03 | 2.83 |
| May 24, 2023 | 2.98 | -0.04 | -1.32% | 3.02 | 3.02 | 2.94 |
| May 23, 2023 | 3.02 | -0.16 | -5.03% | 3.18 | 3.27 | 3.02 |
| May 22, 2023 | 3.17 | 0.10 | 3.26% | 3.07 | 3.27 | 3.03 |
| May 19, 2023 | 2.97 | 0.04 | 1.37% | 2.93 | 3.00 | 2.86 |
| May 18, 2023 | 2.86 | -0.04 | -1.38% | 2.90 | 2.91 | 2.76 |
| May 17, 2023 | 2.89 | -0.04 | -1.37% | 2.93 | 2.94 | 2.84 |
| May 16, 2023 | 2.90 | -0.03 | -1.02% | 2.93 | 2.95 | 2.81 |
| May 15, 2023 | 2.94 | 0.06 | 2.08% | 2.88 | 3.01 | 2.84 |
| May 12, 2023 | 2.83 | -0.29 | -9.29% | 3.12 | 3.16 | 2.81 |
| May 11, 2023 | 3.10 | 0.06 | 1.97% | 3.04 | 3.17 | 2.98 |
| May 10, 2023 | 3.03 | -0.13 | -4.11% | 3.16 | 3.16 | 2.91 |
| May 9, 2023 | 3.00 | -0.24 | -7.41% | 3.24 | 3.24 | 2.96 |
| May 8, 2023 | 3.23 | -0.27 | -7.71% | 3.50 | 3.53 | 3.20 |
| May 5, 2023 | 3.45 | 0.36 | 11.65% | 3.09 | 3.75 | 3.05 |
| May 4, 2023 | 3.05 | 0.33 | 12.13% | 2.72 | 3.14 | 2.69 |
| May 3, 2023 | 2.72 | 0.29 | 11.93% | 2.43 | 2.75 | 2.38 |
Lexicon Events
| Hora (UTC) (UTC) | País | Evento |
|---|---|---|
| Monday, July 31, 2023 | ||
| Hora (UTC) (UTC) 10:59 | País US
| Evento Q2 2023 Lexicon Pharmaceuticals Inc Earnings Release Q2 2023 Lexicon Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
| Tuesday, November 7, 2023 | ||
| Hora (UTC) (UTC) 10:59 | País US
| Evento Q3 2023 Lexicon Pharmaceuticals Inc Earnings Release Q3 2023 Lexicon Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Ingresos totales | 0.139 | 0.298 | 23.995 | 322.073 | 63.209 |
| Ingresos | 0.139 | 0.298 | 23.995 | 322.073 | 63.209 |
| Coste de los ingresos, total | 0 | 0 | 1.929 | 3.231 | 2.491 |
| Beneficio bruto | 0.139 | 0.298 | 22.066 | 318.842 | 60.718 |
| Gastos totales de explotación | 100.899 | 87.388 | 70.792 | 180.628 | 166.488 |
| Gastos de venta/general/administración Gastos, total | 48.083 | 32.342 | 47.23 | 56.835 | 63.754 |
| Investigación y desarrollo | 52.816 | 55.046 | 153.621 | 91.924 | 100.243 |
| Other Operating Expenses, Total | 0 | 0 | |||
| Ingresos de explotación | -100.76 | -87.09 | -46.797 | 141.445 | -103.279 |
| Ingresos por intereses (gastos), netos No operativos | -2.78 | -0.802 | -14.544 | -20.676 | -20.777 |
| Otros, netos | 1.596 | 0.134 | 2.767 | 3.35 | 3.508 |
| Ingresos netos antes de impuestos | -101.944 | -87.758 | -58.574 | 124.119 | -120.548 |
| Ingresos netos después de impuestos | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
| Beneficio neto antes de partidas extra. Elementos | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
| Ingresos netos | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
| Beneficio neto diluido | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
| Promedio ponderado de acciones diluidas | 165.733 | 145.652 | 110.841 | 116.747 | 105.83 |
| BPA diluido sin partidas extraordinarias | -0.61511 | -0.60252 | -0.52845 | 1.11466 | -1.13907 |
| BPA normalizado diluido | -0.61511 | -0.60252 | -1.71924 | 1.2741 | -1.13907 |
| Total de partidas extraordinarias | 0 | ||||
| Gastos (ingresos) extraordinarios | 0 | 0 | -131.988 | 28.638 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Ingresos totales | 0.024 | 0.028 | 0.039 | 0.035 | 0.037 |
| Ingresos | 0.024 | 0.028 | 0.039 | 0.035 | 0.037 |
| Coste de los ingresos, total | |||||
| Beneficio bruto | |||||
| Gastos totales de explotación | 31.166 | 30.306 | 23.134 | 24.042 | 23.417 |
| Gastos de venta/general/administración Gastos, total | 19.14 | 16.329 | 12.577 | 10.686 | 8.491 |
| Investigación y desarrollo | 12.026 | 13.977 | 10.557 | 13.356 | 14.926 |
| Ingresos de explotación | -31.142 | -30.278 | -23.095 | -24.007 | -23.38 |
| Ingresos por intereses (gastos), netos No operativos | -1.821 | -1.103 | -0.864 | -0.703 | -0.11 |
| Otros, netos | 1.029 | 0.887 | 0.572 | 0.123 | 0.014 |
| Ingresos netos antes de impuestos | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
| Ingresos netos después de impuestos | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
| Beneficio neto antes de partidas extra. Elementos | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
| Ingresos netos | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
| Beneficio neto diluido | -31.934 | -30.494 | -23.387 | -24.587 | -23.476 |
| Promedio ponderado de acciones diluidas | 189.014 | 188.98 | 174.904 | 149.616 | 149.15 |
| BPA diluido sin partidas extraordinarias | -0.16895 | -0.16136 | -0.13371 | -0.16433 | -0.1574 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA normalizado diluido | -0.16895 | -0.16136 | -0.13371 | -0.16433 | -0.1574 |
| Gastos (ingresos) extraordinarios | 0 |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 140.866 | 88.921 | 157.719 | 337.754 | 173.324 |
| Efectivo e inversiones a corto plazo | 138.357 | 86.743 | 152.275 | 271.659 | 160.052 |
| Efectivo y Equivalentes | 46.345 | 64.065 | 126.263 | 36.112 | 80.386 |
| Inversiones a corto plazo | 92.012 | 22.678 | 26.012 | 235.547 | 79.666 |
| Total deudores, neto | 0.028 | 0.014 | 0.395 | 56.532 | 5.924 |
| Accounts Receivable - Trade, Net | 0.028 | 0.014 | 0.395 | 56.532 | 5.924 |
| Prepaid Expenses | 2.481 | 2.164 | 5.049 | 5.32 | 2.668 |
| Total Assets | 194.299 | 136.909 | 203.788 | 417.715 | 284.136 |
| Property/Plant/Equipment, Total - Net | 4.371 | 3.476 | 1.495 | 15.747 | 15.865 |
| Property/Plant/Equipment, Total - Gross | 8.355 | 8.329 | 7.31 | 77.488 | 75.871 |
| Accumulated Depreciation, Total | -3.984 | -4.853 | -5.815 | -61.741 | -60.006 |
| Goodwill, Net | 44.543 | 44.543 | 44.543 | 44.543 | 44.543 |
| Intangibles, Net | 0 | 19.716 | 50.119 | ||
| Other Long Term Assets, Total | 4.519 | -0.031 | 0.031 | -0.045 | 0.285 |
| Total Current Liabilities | 23.172 | 22.124 | 46.806 | 65.341 | 36.751 |
| Accounts Payable | 10.395 | 9.152 | 5.469 | 12.178 | 17.759 |
| Accrued Expenses | 12.373 | 10.469 | 29.691 | 42.151 | 14.482 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 11.646 | 11.012 | 1.115 | |
| Other Current Liabilities, Total | 0.404 | 2.503 | 0 | 3.395 | |
| Total Liabilities | 77.175 | 23.314 | 47.417 | 300.614 | 310.541 |
| Total Long Term Debt | 48.579 | 0 | 0 | 234.171 | 243.887 |
| Long Term Debt | 48.579 | 0 | 234.171 | 243.887 | |
| Deferred Income Tax | 0 | 6.014 | |||
| Other Liabilities, Total | 5.424 | 1.19 | 0.611 | 1.102 | 23.889 |
| Total Equity | 117.124 | 113.595 | 156.371 | 117.101 | -26.405 |
| Common Stock | 0.189 | 0.15 | 0.142 | 0.106 | 0.106 |
| Additional Paid-In Capital | 1709.14 | 1608.75 | 1561.1 | 1462.17 | 1447.95 |
| Retained Earnings (Accumulated Deficit) | -1589.72 | -1487.78 | -1400.02 | -1341.44 | -1471.58 |
| Treasury Stock - Common | -2.061 | -7.518 | -4.843 | -3.817 | -2.876 |
| Other Equity, Total | -0.428 | -0.01 | -0.006 | 0.084 | -0.012 |
| Total Liabilities & Shareholders’ Equity | 194.299 | 136.909 | 203.788 | 417.715 | 284.136 |
| Total Common Shares Outstanding | 188.726 | 148.917 | 141.496 | 106.272 | 105.926 |
| Total Inventory | 0 | 4.243 | 4.68 | ||
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 109.546 | 140.866 | 139.063 | 64.898 | 88.431 |
| Efectivo e inversiones a corto plazo | 105.937 | 138.357 | 136.203 | 61.968 | 86.502 |
| Efectivo y Equivalentes | 26.001 | 46.345 | 18.834 | 21.45 | 59.52 |
| Inversiones a corto plazo | 79.936 | 92.012 | 117.369 | 40.518 | 26.982 |
| Total deudores, neto | 0.261 | 0.028 | 0.039 | 0.034 | 0.037 |
| Accounts Receivable - Trade, Net | 0.261 | 0.028 | 0.039 | 0.034 | 0.037 |
| Prepaid Expenses | 3.348 | 2.481 | 2.821 | 2.896 | 1.892 |
| Total Assets | 162.716 | 194.299 | 191.685 | 112.325 | 136.178 |
| Property/Plant/Equipment, Total - Net | 8.607 | 4.371 | 8.032 | 2.835 | 3.242 |
| Property/Plant/Equipment, Total - Gross | 6.303 | 8.355 | 6.109 | 6.105 | 6.104 |
| Accumulated Depreciation, Total | -4.096 | -3.984 | -5.177 | -5.07 | -4.962 |
| Goodwill, Net | 44.543 | 44.543 | 44.543 | 44.543 | 44.543 |
| Other Long Term Assets, Total | 0.02 | 4.519 | 0.047 | 0.049 | -0.038 |
| Total Current Liabilities | 20.371 | 23.172 | 18.445 | 16.862 | 18.905 |
| Accounts Payable | 10.311 | 10.395 | 9.427 | 7.347 | 9.321 |
| Accrued Expenses | 9.576 | 12.373 | 8.299 | 9.038 | 8.864 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | |||||
| Total Liabilities | 74.67 | 77.175 | 47.667 | 41.495 | 43.48 |
| Total Long Term Debt | 48.845 | 48.579 | 23.784 | 23.631 | 23.477 |
| Other Liabilities, Total | 5.454 | 5.424 | 5.438 | 1.002 | 1.098 |
| Total Equity | 88.046 | 117.124 | 144.018 | 70.83 | 92.698 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.19 | 0.189 | 0.189 | 0.15 | 0.15 |
| Additional Paid-In Capital | 1712.56 | 1709.14 | 1705.61 | 1608.73 | 1605.9 |
| Retained Earnings (Accumulated Deficit) | -1621.65 | -1589.72 | -1559.23 | -1535.84 | -1511.25 |
| Treasury Stock - Common | -2.885 | -2.061 | -2.061 | -2.061 | -2.061 |
| Other Equity, Total | -0.163 | -0.428 | -0.491 | -0.15 | -0.037 |
| Total Liabilities & Shareholders’ Equity | 162.716 | 194.299 | 191.685 | 112.325 | 136.178 |
| Total Common Shares Outstanding | 189.562 | 188.726 | 188.726 | 149.626 | 149.594 |
| Other Current Liabilities, Total | 0.484 | 0.404 | 0.719 | 0.477 | 0.72 |
| Long Term Debt | 48.845 | 48.579 | 23.784 | 23.631 | 23.477 |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Ingresos netos/Línea de salida | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
| Efectivo de actividades de explotación | -88.851 | -87.017 | -142.969 | 113.807 | -148.607 |
| Efectivo de actividades de explotación | 0.427 | 0.292 | 2.934 | 3.654 | 3.683 |
| Deferred Taxes | 0 | 0 | -6.014 | 0 | |
| Partidas no monetarias | 12.264 | 10.68 | -118.408 | 44.321 | 13.032 |
| Intereses pagados en efectivo | 2.289 | 0.799 | 17.353 | 19.211 | 16.465 |
| Cambios en el capital circulante | 0.402 | -10.231 | 31.079 | -58.287 | -44.774 |
| Efectivo de actividades de inversión | -71.078 | 2.11 | 380.756 | -155.855 | 169.576 |
| Gastos de capital | -1.326 | -1.221 | -0.087 | -0.07 | -0.095 |
| Otras partidas de flujo de caja de inversión, total | -69.752 | 3.331 | 380.843 | -155.785 | 169.671 |
| Efectivo procedente de actividades de financiación | 142.209 | 22.709 | -147.636 | -2.226 | -2.244 |
| Emisión (retiro) de acciones, neto | 93.341 | 34.409 | 68.944 | -0.941 | -0.24 |
| Emisión (amortización) de deuda, neta | 48.868 | -11.7 | -216.58 | -1.285 | -2.004 |
| Variación neta de la tesorería | -17.72 | -62.198 | 90.151 | -44.274 | 18.725 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -31.934 | -101.944 | -71.45 | -48.063 | -23.476 |
| Cash From Operating Activities | -31.613 | -88.851 | -67.282 | -47.843 | -23.421 |
| Cash From Operating Activities | 0.112 | 0.427 | 0.324 | 0.216 | 0.109 |
| Non-Cash Items | 3.68 | 12.264 | 8.648 | 5.783 | 2.797 |
| Cash Interest Paid | 1.556 | 2.289 | 1.281 | 0.634 | 0.085 |
| Changes in Working Capital | -3.471 | 0.402 | -4.804 | -5.779 | -2.851 |
| Cash From Investing Activities | 12.093 | -71.078 | -95.252 | -18.056 | -4.408 |
| Capital Expenditures | -0.248 | -1.326 | -0.08 | -0.076 | -0.076 |
| Other Investing Cash Flow Items, Total | 12.341 | -69.752 | -95.172 | -17.98 | -4.332 |
| Cash From Financing Activities | -0.824 | 142.209 | 117.303 | 23.284 | 23.284 |
| Issuance (Retirement) of Stock, Net | -0.824 | 93.341 | 93.404 | -0.864 | -0.864 |
| Issuance (Retirement) of Debt, Net | 0 | 48.868 | 23.899 | 24.148 | 24.148 |
| Net Change in Cash | -20.344 | -17.72 | -45.231 | -42.615 | -4.545 |
| Deferred Taxes |
| Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
|---|---|---|---|---|---|---|
| Artal International S.C.A. | Investment Advisor | 45.506 | 86262020 | 0 | 2023-03-31 | LOW |
| BVF Partners L.P. | Hedge Fund | 8.5192 | 16149179 | 0 | 2023-03-31 | LOW |
| Ulys, L.L.C. | Investment Advisor | 2.7979 | 5303814 | 0 | 2022-08-01 | |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.792 | 5292626 | 43032 | 2023-03-31 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 2.7644 | 5240247 | -11438 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.6709 | 5062976 | -201281 | 2023-03-31 | LOW |
| Invus Public Equities Advisors, LLC | Investment Advisor | 1.8549 | 3516214 | 0 | 2023-03-31 | LOW |
| JP Morgan Asset Management | Investment Advisor | 1.6081 | 3048374 | 56229 | 2023-03-31 | LOW |
| D. E. Shaw & Co., L.P. | Hedge Fund | 1.5515 | 2940997 | -136976 | 2023-03-31 | LOW |
| New Enterprise Associates (NEA) | Venture Capital | 1.2567 | 2382286 | 0 | 2023-03-31 | LOW |
| Pinnacle Associates Ltd. | Investment Advisor/Hedge Fund | 1.0235 | 1940224 | 7447 | 2023-03-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.9102 | 1725409 | 117468 | 2023-03-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.8251 | 1564098 | 47623 | 2023-03-31 | LOW |
| Coats Lonnel | Individual Investor | 0.3927 | 744359 | 158356 | 2023-02-28 | LOW |
| Fisher Investments | Investment Advisor/Hedge Fund | 0.38 | 720243 | 0 | 2023-03-31 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.3794 | 719182 | 306384 | 2023-03-31 | LOW |
| Charles Schwab Investment Management, Inc. | Investment Advisor | 0.3633 | 688611 | -7329 | 2023-03-31 | LOW |
| Parkman Healthcare Partners LLC | Hedge Fund | 0.3563 | 675328 | 254126 | 2023-03-31 | HIGH |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.3561 | 675018 | -19915 | 2023-03-31 | LOW |
| Asset Management One Co., Ltd. | Investment Advisor/Hedge Fund | 0.3194 | 605528 | 605528 | 2022-08-31 | LOW |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group535K+
Traders
87K+
Clientes activos mensualmente
$113M+
Volumen mensual de inversión
$64M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
Comisión de la operación
0
- 1:1
Apalancamiento
1:1
- 20
- 100
- 500
- 1000
- 10000
Inversión
Tamaño de la operación (Apalancamiento x Inversión)
Apertura
Cierre
En corto En largo
Lexicon Company profile
Sobre Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. es una empresa biofarmacéutica. La empresa se centra en el descubrimiento, desarrollo y comercialización de productos farmacéuticos para el tratamiento de enfermedades humanas. Su cartera de productos incluye Sotagliflozin, LX9211 y LX2761. La sotagliflozina es un compuesto de molécula pequeña de administración oral que se está desarrollando para el tratamiento de la insuficiencia cardíaca y la diabetes de tipo I, y la diabetes de tipo II, la insuficiencia cardíaca y la enfermedad renal crónica. El LX9211 es un compuesto de pequeña molécula de administración oral que se está desarrollando para el tratamiento del dolor neuropático. La empresa está realizando un ensayo clínico de fase II de LX9211 en el dolor neuropático periférico diabético y un segundo ensayo clínico de fase II de LX9211 en la neuralgia posherpética. El LX2761 es un compuesto de molécula pequeña de administración oral que está diseñado para inhibir el cotransportador de sodio-glucosa 1 (SGLT1) localmente en el tracto gastrointestinal sin inhibir el cotransportador de sodio-glucosa 2 (SGLT2) en el riñón.
El precio actual de la acción Lexicon en tiempo real es 2.69 USD. El gráfico de la acción permite a los inversores comprender mejor el rendimiento y el precio de la acción y tomar decisiones informadas al negociar acciones y CFD.
Descubra más acciones con gráficos, datos vitales y actualizaciones de precios en tiempo real: Alfi, Inc., Fanuc Corporation, Banco Macro S.A., Analog Devices, Inc., Nobia y TriCo. Para obtener más información, consulte los perfiles de las empresas en Capital.com.
| Industry: | Bio Therapeutic Drugs |
8800 Technology Forest Place
8800 Technology Forest Place
77381
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 535.000 traders de todo el mundo que eligen operar con Capital.com